Summary
Nicotinamide has been given both before and after clinical onset of Type 1 (insulin-dependent) diabetes mellitus in an attempt to prolong beta-cell survival. Nicotinic acid, structurally similar to nicotinamide, induces insulin resistance and increases insulin secretion in healthy individuals. It is not known if nicotinamide has similar effects. Since insulin secretion, as measured by the acute insulin response to intravenous glucose, is used to predict diabetes and to monitor therapy, the effects of nicotinamide must be established before trials in individuals at high risk of progression to Type 1 diabetes can be interpreted. Intravenous tolerance tests were performed according to the ICARUS standard protocol in 10 healthy, adult subjects (age 32±5.7 years) before and after 14 days of treatment with nicotinamide 25 mg · kg−1 · day−1. The acute insulin response after nicotinamide did not differ from the control study, whether measured as the incremental 0–10 min insulin area (278±142 vs 298±130mU · l−1 · 10 min−1) or as the 1±3 min insulin level (78±39 vs 81±44 mU/l). The late insulin response was equally unaffected, as were basal insulin (5.2±1.6 vs 5.6±2.1 mU/l) and glucose (5.0±0.4 vs 4.9±0.2 mmol/l) levels and glucose disposal rates (1.98±0.88 vs 2.04±0.68%/min). Nicotinamide does not affect insulin secretion and glucose kinetics in normal subjects, confirming its suitability for trials designed to delay or prevent the onset of Type 1 diabetes.
Article PDF
Similar content being viewed by others
References
Yamada K, Nonaka K, Hanafusa T, Miyazaky FM, Toyoshima H, Tauri S (1982) Preventive and therapeutic effects of large dose nicotinamide injections on diabetes associated with insulitis. Diabetes 31: 749–753
Elliott RB, Chase PH (1991) Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 34: 362–365
Lee YC, Chandler JLR, Gholson RK (1971) Quantitative studies on the excretory metabolites of nicotinic acid and nicotinamide in normal, hypophysectomized, and germ-free rats. In: Gey KF, Carlson LA (eds) Metabolic effects of nicotinic acid and its derivatives. Hans Huber, Berne, pp 133–147
Kahn SE, Beard JC, Schwartz MW et al. (1989) Increased betacell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced resistance. Diabetes 38: 562–568
McCulloch D, Kahn SE, Schwatz MW, Koerker DJ, Palmer JP (1991) Effect on nicotinic acid-induced insulin resistance on pancreatic B cell in normal and streptozocin-treated baboons. J Clin Invest 87: 1395–1401
Vardi P, Crisa L, Jackson RA et al. (1991) Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 34: 93–102
Tarn AC, Smith CP, Spencer KM, Bottazzo GF, Gale EAM (1987) Type 1 (insulin-dependent) diabetes: a disease of slow clinical onset? BMJ 294: 342–345
Bingley PJ, Colman PG, Eisenbarth GS et al. (1992) Standardization of the intravenous glucose tolerance test for use in the prediction of insulin-dependent diabetes. Diabetes Care 15: 1313–1316
Bingley PJ, Bonifacio E, Gale EAM (1993) Can we really predict IDDM? Diabetes 42: 213–220
Chase P, Dupre J, Mahon J et al. (1992) Nicotinamide and prevention of diabetes. Lancet 339: 1051–1052
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bingley, P.J., Caldas, G., Bonfanti, R. et al. Nicotinamide and insulin secretion in normal subjects. Diabetologia 36, 675–677 (1993). https://doi.org/10.1007/BF00404080
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00404080